• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
3 Steal-of-a-Deal Stocks to Snap Up Right Now ↗
February 26, 2024
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now. 
Via InvestorPlace
News headline image
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment ↗
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
News headline image
Get Rich Quick with These 7 Growth Stocks to Buy Now ↗
February 20, 2024
Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand. 
Via InvestorPlace
News headline image
7 Dividend Stocks to Buy at a 52-Week Low ↗
February 12, 2024
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround. 
Via InvestorPlace
News headline image
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market ↗
February 01, 2024
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock. 
Via InvestorPlace
News headline image
Looking Into Seagen's Recent Short Interest ↗
December 13, 2023
 
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) is a Leading Gainer in 12/12 Morning Trading
December 12, 2023
Via Investor Brand Network
News headline image
What the Options Market Tells Us About Seagen ↗
December 11, 2023
 
Via Benzinga
News headline image
3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
News headline image
How To Earn $500 A Month From Pfizer Stock ↗
January 02, 2024
Pfizer Inc. (NYSE: PFE) shares closed almost flat on Friday, but lost around 44% during 2023. 
Via Benzinga
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
3 Stocks That Are About to Get Absolutely Crushed ↗
December 14, 2023
These are a few different companies that are experiencing difficult times and that are expected to keep falling. 
Via InvestorPlace
News headline image
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today ↗
December 07, 2023
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today ↗
November 20, 2023
 
Via Benzinga
News headline image
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast ↗
December 14, 2023
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE),  
Via Benzinga
News headline image
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years? ↗
December 14, 2023
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen. 
Via The Motley Fool
News headline image
3 Sleepy Stocks Ready to Wake up in 2024 ↗
December 13, 2023
Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024. 
Via InvestorPlace
News headline image
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades' ↗
December 13, 2023
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK) 
Via Benzinga
News headline image
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints ↗
December 13, 2023
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
News headline image
Why Is US Pharma Giant Pfizer Stock Trading Lower Today? ↗
December 13, 2023
Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDAQ: SGEN) transaction. 
Via Benzinga
News headline image
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition ↗
December 12, 2023
Pfizer Inc (NYSE: PFE)  
Via Benzinga
News headline image
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal ↗
December 12, 2023
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
News headline image
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
December 10, 2023
From Seagen Inc.
Via Business Wire
News headline image
3 Blue-Chip Stocks Set to Make a Comeback in 2024 ↗
December 08, 2023
These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth. 
Via InvestorPlace
News headline image
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
December 06, 2023
From Seagen Inc.
Via Business Wire
News headline image
ImmunoGen Stock Nearly Doubled On Thursday: What Happened? ↗
November 30, 2023
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
News headline image
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
November 30, 2023
From Seagen Inc.
Via Business Wire
News headline image
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love ↗
November 30, 2023
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless. 
Via InvestorPlace
News headline image
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023 ↗
November 19, 2023
Here are just a few of the most undervalued sleeper stocks investors may want to consider heading into the new year. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
November 10, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap